A Second Dose of Measles Vaccine (MV) in the Second Year of Life

Bandim Health Project

Status: Completed

Conditions: Child Morbidity; Child Mortality

Treatments: Biological: Measles vaccine

Study type: Interventional

Funder types: Other

Identifiers

NCT02943681

MV18Months

Details and patient eligibility

About

This study evaluates the non-specific effects on child mortality and morbidity of a second dose of measles in the second year of life. Half of the study participants will receive a second dose of measles vaccine at 18 months of age while the other half will receive a second dose of measles by 4 years of age or at the end of the study.

Enrollment: 3,812 patients

Sex: All

Ages: 18 to 24 months old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Children need to have received the third dose of inactivated vaccines (Penta, PCV13 and IPV) before measles vaccination.

Exclusion criteria

• Having severe malformations that impairs their health
• Having received a second dose of measles vaccine
• Severely ill (requiring hospitalization) upon clinical examination

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

3,812 participants in 2 patient groups

Measles vaccine

Experimental group

Description:

Measles vaccine, 1 dose of 0.5 ml

Treatment:

Biological: Measles vaccine

Control

No Intervention group

Description:

Nothing